These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29214575)

  • 1. Health Technology Assessment and Appraisal of Therapies for Rare Diseases.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Adv Exp Med Biol; 2017; 1031():221-231. PubMed ID: 29214575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 4. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Front Public Health; 2016; 4():214. PubMed ID: 27747207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technologies for rare diseases: does conventional HTA still apply?
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):315-7. PubMed ID: 24702042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
    Angelis A; Montibeller G; Hochhauser D; Kanavos P
    BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies.
    Coyle D; Durand-Zaleski I; Farrington J; Garrison L; Graf von der Schulenburg JM; Greiner W; Longworth L; Meunier A; Moutié AS; Palmer S; Pemberton-Whiteley Z; Ratcliffe M; Shen J; Sproule D; Zhao K; Shah K
    Eur J Health Econ; 2020 Dec; 21(9):1421-1437. PubMed ID: 32794011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple criteria decision analysis for health technology assessment.
    Thokala P; Duenas A
    Value Health; 2012 Dec; 15(8):1172-81. PubMed ID: 23244821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TESTING MULTI-CRITERIA DECISION ANALYSIS FOR MORE TRANSPARENT RESOURCE-ALLOCATION DECISION MAKING IN COLOMBIA.
    Castro Jaramillo HE; Goetghebeur M; Moreno-Mattar O
    Int J Technol Assess Health Care; 2016 Jan; 32(4):307-314. PubMed ID: 27691990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
    Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
    Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA.
    Mühlbacher AC; Kaczynski A
    Appl Health Econ Health Policy; 2016 Feb; 14(1):29-40. PubMed ID: 26519081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
    Angelis A; Kanavos P
    Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of HTA research on policy decision-making.
    Youngkong S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion.
    Iskrov G; Dermendzhiev S; Miteva-Katrandzhieva T; Stefanov R
    Front Pharmacol; 2016; 7():252. PubMed ID: 27582707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging the Gap between Health and Social Care for Rare Diseases: Key Issues and Innovative Solutions.
    Castro R; Senecat J; de Chalendar M; Vajda I; Dan D; Boncz B;
    Adv Exp Med Biol; 2017; 1031():605-627. PubMed ID: 29214594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study.
    Wahlster P; Goetghebeur M; Schaller S; Kriza C; Kolominsky-Rabas P;
    Health Res Policy Syst; 2015 Apr; 13():24. PubMed ID: 25928535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.